Myeloma Minute: New IMWG Response Criteria

 

IMWG's New Response Criteria Provides Clinical Trial Endpoints and a Framework for a Cure

The IMF’s research division, the International Myeloma Working Group, has established the scientific definition on the essential requirements for a pathway to cure multiple myeloma. Published on July 27, 2016 in The Lancet Oncology, the 2016 criteria define new response categories of minimal residual disease (MRD) negativity in order to standardize testing in patients who are having an excellent response to treatment in clinical trials. The new response criteria updates those set by the group in 2006. To learn more about new IMWG response criteria, click HERE. Listen to The Lancet podcast interview with Dr. Kumar about the new response criteria HERE.

 

Darzalex (daratumumab) Granted Breakthrough Therapy Designation, Along With a Cautionary Note

Darzalex®, or daratumumab, has been in the news this week, notes IMF Chairman Dr. Brian Durie in his blog. The drug has been granted “Breakthrough Therapy” designation by the US Food and Drug Administration for use in combination with Revlimid® (lenalidomide) and dexamethasone, and Velcade® (bortezomib) and dexamethasone for the treatment of multiple myeloma patients who have received at least one previous therapy. And, according to a report in the New England Journal of Medicine, it consistently interferes with certain blood test results. To read Dr. Durie’s blog, click HERE.

 

IMF's Community Picnic Day — Fabulous and Free to All

Take a break from the PokémonGo craze and come to the IMF’s inaugural Community Picnic Day! Thanks to event sponsor Amgen, anyone can attend this exciting event on Sunday, August 21st, in Los Angeles’s beautiful Griffith Park, for FREE! Open to all ages, the IMF Community Picnic Day will provide fun for the whole family. Scheduled activities include yoga sessions, Tai Chi instruction, a healthy cooking demonstration, art therapy, and a 1K fun run for kids. Don’t miss out! Click HERE to join in on the fun. We look forward to closing out the summer with you!

New on IMF-TV: Another Exciting Black Swan Research Initiative-Supported Clinical Trial

Dr. Jens Hillengass (University of Heidelberg) is lead investigator for a Black Swan Research Initiative®-supported study that assesses molecular disease heterogeneity in patients with multiple myeloma by imaging guided biopsy. In this video interview with IMF-TV, Dr. Hillengass explains the goals of this trial.

Paddle to Battle Multiple Myeloma: 21st Century Frontiersman's Kayak Crusade Supports IMF Research

John Taussig, a modern-day frontiersman, will kayak up the Inside Passage, a water route that weaves through a maze of islands starting at the Puget Sound in Washington State and extending north along the British Columbia Coast to the Alaska Panhandle. His journey is to raise awareness and money to support IMF’s research program. No stranger to the outdoors, Taussig is the founder of the nonprofit Backcountry Medical Guides, which focus on wilderness, maritime, and remote emergency medicine. John is a flight paramedic aboard a medevac helicopter in central California as well as a licensed sea captain. John’s travels in a kayak up the Inland Passage mark a couple of firsts: this is his first kayak journey along this path, and it is also his first major endeavor to raise money in honor of two family members—his mother Anne and his uncle Tom, who were both recently diagnosed with multiple myeloma. Impressed by John’s initiative, a generous donor has offered to match all donations to Paddle to Battle Multiple Myeloma dollar for dollar. Please support John’s extraordinary efforts, click HERE.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.